GLPwatch
Effect of Exenatide on Cortisol Secretion
NCT03160261 · Completed
Last updated 2026-05-28This trial tested whether the medication exenatide affects cortisol levels in healthy individuals.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design open-label (no blinding) diagnostic study
Participants 10 people
Who can join Ages 18–50 · all sexes Healthy volunteers accepted.
Timeline Started 2017-09 · est. completion 2017-12
Where 1 site · Estonia
What this study is testing ClinicalTrials.gov NCT03160261 ↗
Description as written by the study sponsor.
The primary aim of the study is to describe the effect of single dose of 10 micrograms (μg) exenatide given subcutaneously (s/c) on cortisol secretion. Secondary outcomes involve ACTH and glucose levels.
Treatments tested
- Exenatide Injection Drug
Single injection of Exenatide 10μg subcutaneously
| Main thing measured | Cortisol peak |
|---|---|
| Sponsor | University of Tartu |
| Conditions studied | Healthy |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03160261 ↗